241 Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, Ferrante M, Cleynen I, et al. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27(10):1564-1575. doi: 10.1093/ibd/izab032. West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017;23(5):579-589. doi: 10.1038/nm.4307. Place SP. Single-pointmutation ina conservedTPRdomainof Hipdisrupts enhancement of glucocorticoid receptor signaling. Cell Stress Chaperones 2011;16(4):469-74. doi: 10.1007/s12192-010-0254-2. Bai R, Shi Z, Zhang JW, Li D, Zhu YL, Zheng S. ST13, a proliferation regulator, inhibits growth and migration of colorectal cancer cell lines. J Zhejiang Univ Sci B 2012;13(11):884-893. doi: 10.1631/jzus.B1200037. Wang LB, Zheng S, Zhang SZ, Peng JP, Ye F, Fang SC, et al. Expression of ST13 in colorectal cancer and adjacent normal tissues. World J Gastroenterol 2005;11(3):336-9. doi: 10.3748/wjg.v11.i3.336. 50 51 52 53 54 Mucosal host-microbe interactions in IBD
RkJQdWJsaXNoZXIy MjY0ODMw